Cumulative Index 1987

Volume 7

April	UPPER RESPIRATORY DISORDERS, pages 1–178
August	COMMON ALLERGIES AND ALLERGIC DISEASES, pages 179–354
December	COMMON ALLERGIES AND ALLERGIC DISEASES II, pages 355–509

Note: Page numbers of article titles are in **boldface** type.

Acaricides, 453–454
Acquired immunodeficiency syndrome (AIDS), trimethoprim-sulfamethoxazole reactions, 294–295
Active immunization. See *Immunization.*
Airflow obstruction tests, 18–25
  computed tomography, 18
  nasal peak flow meters, 18–20
  rhinomanometric methods, 21–25
Allergens, **191–203**
  animals, 199, 457–458
  arthropods, 199–200
  bronchial provocation with, 243–244
  challenge, 28–31
    nasal response, 30–31
    protocols, 30
  cockroach, 458–459
  cross-reactivity, assessment of, 194
    clinical applications of, 193–194
  danders, 200–201
  determinant characteristics, 192
  exposure of, 193
  foods, 201–202
  genetic disposition, 192–193
  grasses, 195–196
  immune response and allergenicity, 192
  immunogenicity, 191
  mites, 454–455
  molds, 197–199
  pollens, 194–195
  size, 191–192
  trees, 197
  weeds, 196–197
Allergic contact dermatitis. See *Dermatitis, allergic contact.*
Allergic disease, and asthma, **235–253**
  and atopic dermatitis, **255–264**
  in children, **331–350**
  clinical diagnosis of, **205–219**
    allergy provocation tests, 213–214
    history and physical examination, 205–207
    laboratory studies for atopic disease, 214–216
    skin testing, 207–212
      house dust and mite allergy, 209–210
      mold allergy, 210–212
    in vitro measurement of specific IgE antibody, 212–213
  to drugs, **285–297**
  eosinophil function, 364
  to food, **299–312**
    and migraine, 150
  and otitis media, **371–381**
    cause-effect perspective, 380
    epidemiology, 374
    eustachian tubes, 372–373
      provocation studies, 375
    immunologic mechanisms, 374–375
    methodologic limitations of studies, 373–374
    natural history, 371–372
  to stinging insects, **277–283**
  See also *Drugs, for allergic diseases; Rhinitis, allergic; Upper respiratory tract allergy.*

Allergic headache. See *Headache, allergic.*
Allergy emergencies, **485–500**
  differential diagnosis, 492–493
  etiology, 489–492
  management, 493–496
    complications, 496
    hypotension, 495
    lower airway obstruction, 495
    upper airway obstruction, 493–495
    urticaria and angioedema, 495–496
  pathophysiology, 486–489
  prevention, 496–498
Anaphylaxis. See *Allergy emergencies,*
Anatomy, of nasal polyps,, 106–108
  of sinuses, 383–384
Angioedema, 495–496
  See also *Urticaria and angioedema.*
Animals, allergens of, 199, 457–458
  and asthma, 243
Antibody, IgE, in food allergies, 305–307
  in vitro measurement of, 212–213
Anticholinergic agents, 78–79, 467
Antihistamines, for allergic diseases, 463–464
  mediator effect inhibitors, 71–75
Antral puncture, in chronic sinusitis, 124
Arthropod allergens, 199–200
Aspergillosis, allergic bronchopulmonary, in cystic fibrosis, 396–399
Aspirin, intolerance, and nasal polyps, 112–113
  sensitivity, and asthma, 248
  and urticaria and angioedema, 267
Astemizole, 74–75, 464
Asthma, allergy risk in, **235–253**
    allergen risk, 239–243
      animals, 243
      house dust and house dust mites, 242–243
      molds, 242
      pollens, 241–242
    allergic, immunotherapy, 249–250
    aspirin sensitivity, 248
    atopic, prophylactic measures in, 249
    beta-adrenergic blockers and atopy, 248
    bronchial hyperreactivity and allergy, 244–245
    bronchial provocation with allergens, 243–244
    classification of, 237
    exercise-induced, 248–249
    and food and food additives allergy, 245–246
    genetics of atopy and IgE, 237–239
    and infection and atopy, 245
    occupational, and atopy, 246–248
      smoking, 247–248
  in children, 334–342, 346
    differential diagnosis, 335
    early diagnosis, 335–336
    immunotherapy, 342
    precipitating factors, 336–338
      environmental factors, 336
      exercise, 338
      gastroesophageal reflux, 337
      infection, 336
      psychological factors, 336–337
      sinusitis, 337
    therapy, 338–342
  and migraine, 154
  nonallergic, chronic intermittent obstructive rhinitis, 95–96
  occupational, **313–330**
    allergic, 314–319
    approach to patient, 320–321
    and atopy, 246–248
      smoking, 247–248
    bronchoconstriction, inflammatory, 319–320
    reflex, 319
    diagnostic tests, 321–323
      bronchoprovocation challenges, 322–323
      inhalation challenges, 322
      pulmonary function tests, 322
      skin tests and in vitro IgE tests, 321–322
      workplace challenges, 322
    management, 323–324
    pathogenesis, 314
    pharmacologic agonists, 320
  and sinusitis, 128–129
Atopic dermatitis, **255–264**
  causative effects of food or inhalants, 260–261
  in children, 347
  elimination of food allergens and inhalants, 261–262
  food allergies, 256–259, 345–346
    determination and elimination of, 257–259, 260–262
    prophylaxis by early avoidance of, 256–257
  inhalant allergies, 259, 260–262
  staphylococcal antigens, 260
  treatment of, 262–263
Atopic disease, adverse hypersensitivity reactions, 441–443
  in children, 346–348
    allergic rhinitis, 347–348
    asthma, 346
    atopic dermatitis, 347
    food reactions, 347
  in cystic fibrosis, 393–396
  and IgE, genetics of, 237–239
  laboratory studies for, 214–216
  and nasal polyps, 110–111
  and occupational asthma, 246–248
Atropine, 78
Azatadine, 70
Azelastine, 70–71, 465

Bacterial vaccines, 434–436
Basophils, mediator release from, **179–189**
  histamine release, 184–187
    enhancement of, 185–186
    extrinsic modulation of, 184
    inhibition of, 186–187
  intrinsic releasability, 183–184
  stimulus-response in, 180–182
  mucosal cytology, 17–18
Beclomethasone dipropionate, 82–85
Benzocaine, 415
Beta-adrenergic blockers, and asthma, 248
Biood flow, nasal, 25–26, 41
Bronchial, hyperreactivity, and allergy, 244–245
  provocation with allergens, 243–244
Bronchoconstriction, inflammatory, 319–320
  reflex, 319
Bronchoprovocation challenges, 322–323

Calcium channel blockers, 66–68, 468
cAMP increasers, in rhinitis pharmacotherapy, 69–70
Candidiases hypersensitivity syndrome, 10
Cat allergens, 457–458
Children, allergic, **331–350**
  asthma, 334–342
    differential diagnosis, 335
    early diagnosis, 335–336
    immunotherapy, 342
    precipitating factors, 336–338
      environmental factors, 336
      exercise, 338
      gastroesophageal reflux, 337
      infection, 336
      psychological factors, 336–337
      sinusitis, 337
    therapy, 338–342
  atopic disease, 346–348
    allergic rhinitis, 347–348
    asthma, 346
    atopic dermatitis, 347
    food reactions, 347
  with chronic sinusitis, 127–128
  food sensitivity, 342–346
    and atopic dermatitis, 345–346
    diet and hyperactivity, 344–345
    therapy, 344
  prevention of allergic disease, 333–334
  risk factors, 333
Cholinergic urticaria, 274
Chromates, 416
Churg-Strauss syndrome, 166–168
Cimetidine, 75
Cluster headaches, 148
Cockroach allergens, 458–459
Cold dry air challenge, 50–51
Collagen vascular disease, 270
Corticosteroids, in rhinitis pharmacotherapy, 79–85
  systemic, 79–82
  topical, 82–85
Cromolyn sodium, 63–65
Cross-reactivity of allergens, 193–194
Cystic fibrosis, hypersensitivity responses, **393–406**
  allergic bronchopulmonary aspergillosis, 396–399
  atopy, 393–396
  drug reactions, 401–403
  nasal polyposis, 399–401
Cytology, mucosal, basophils and mast cells, 17–18
  eosinophils, 16–17
  nasal, in upper respiratory tract allergy, 2
Cytotoxicity, of eosinophils, 360

Dander allergens, 200–201
Dermatitis, allergic contact, **407–421**
  clinical presentation, 407–410
  diagnosis, 412–419
    common sensitizers, 412–417
    patch testing, 417–419
  genetic and predisposing factors, 410–411
  management, 420
  microscopic features, 411
  pathogenesis, 411–412
  prevention, 419–420
Diagnosis, of allergic contact dermatitis, 412–419
    common sensitizers, 412–417
    patch testing, 417–419
  of allergic migraine, 154–155
  of allergy emergencies, 492–493
  of nasal polyps. 109
  of sinusitis, 118, 387–388
  of upper respiratory tract allergy, **1–13**
Diary, food/symptom, 304
Diets, diagnostic elimination, in food allergies, 303
  and hyperactive children, 344–345
  for migraine, 155–156
Diphenhydramine, 416
Dog allergens, 457–458
Drugs, for allergic diseases, **463–469**
    anticholinergics, 467
    antihistamines, 463–464
    azelastine, 465
    calcium channel blocking agents, 468
    ketotifen, 465
    nedocromil sodium, 465–466
    xanthine preparations, 466–467
  allergic reactions to, **285–297**, 401–403
    diagnosis, 290–291
    immunologic, 287–290
    nonimmunologic, 285–287

Drugs *(Continued)*
allergic reactions to, prevention, 292
timing of penicillin skin testing, 292–294
trimethoprim-sulfamethoxazole effects in AIDS, 294–295

Ecology, clinical, for upper respiratory tract allergy, 10–11
Education, asthma in children, 338–342
Eicosinoids, 358
Elimination-challenge test, in food allergy, 308–309
Emergencies, allergic. See *Allergy emergencies.*
Environmental factors, and asthma in children, 336
Enzymes, eosinophil-associated, 358
Eosinophils, **355–370**
activated, 358
eosinophilia and associated diseases, 362–368
allergic diseases, 364
gastrointestinal tract disorders, 367
hematologic malignancies, 367–368
hypereosinophilic syndrome, 368
immunologic disorders, 367
infections, 364
lymphoreticular disease, 367–368
neoplasia, 367–368
parasitic infections, 362–364
respiratory tract disorders, 364–366
skin disorders, 366–367
functions of, 360–361
cytotoxicity, 360
in immediate hypersensitivity, 361
mediator of inflammation and tissue damage, 361
phagocytosis, 360
mucosal cytology, 16–17
production and distribution, 358–359
structure of, 355–358
cellular components, 355
general features, 355
granule-associated proteins, 355–357
membrane-associated proteins, 357–358
Eosinophilia, with episodic angioedema, 270
Eosinophilic chronic rhinitis syndromes, 93–94
Eosinophilopoiesis, 358
Epidemiology, of allergy and otitis media, 374
of nasal polyps, 106
of otitis media with effusion, 133–134
Ethylenediamine, 415
Etiology, of allergy emergencies, 489–492
of otitis media with effusion, 137–144
immunologic and allergic aspects, 140–144
infectious aspects, 137–139
Eustachian tubes, 372–373, 375
Exercise, and asthma, 248–249
in children, 338

Fiberoptic rhinoscopy, for rhinitis, 15–16
of sinusitis, 124
Flunisolide, 82–85
Fluocortin, 82–85
Food allergies, **299–312**
allergens of, 201–202
allergies, in atopic dermatitis, 256–259, 260–262
in children, 342–347
and atopic dermatitis, 345–346
diet and hyperactivity, 344–345
therapy, 344
and food additives, allergy in asthma, 245–246
diagnosis, 301–307
elimination diets, 303
food/symptom diary, 304
IgE antibody assays, 305–307
laboratory tests, 303, 307
medical history, 301–303
physical examination, 303
skin testing, 304–305
pathogenesis of, 299–301
verification, 307–309
elimination-challenge test, 308–309
inhalation food challenge, 309
Formaldehyde, and allergic contact dermatitis, 416
Fungi, in house dust, 455–457

Gastroesophageal reflux, 337
Gastrointestinal tract disorders, and eosinophils, 367
Genetics, of allergens, 192–193
of allergic contact dermatitis, 410–411
of atopy and IgE, 237–239
Glucocorticoids, 79–81
Granule-associated proteins in eosinophils, 355–357
Granuloma, midline, 170
Grass allergens, 195–196

Headache, allergic, **147–157**
cluster headaches (Horton's histamine cephalgia), 148
migraine, 149–156
asthma as model for, 154
definition of, 149
diet trial, 155–156
epidemiology, 149–150
historical review, 150–153
history taking, 154

laboratory tests, 155
pathophysiology, 153–154
physical examination, 155
Hematologic malignancies, and eosinophils, 367–368
Hereditary angioedema, 266–267, 273
Histamine, in allergic rhinitis, 45–46
release from mast cells and basophils, 184–187
enhancement of, 185–186
extrinsic modulation of, 184
inhibition of, 186–187
in urticaria and angioedema, 267
Histology, of nose, 39–42
Histopathology, of nasal polyps, 108–109
Horton's histamine cephalgia, 148
House dust, and asthma, 242–243
cat and dog allergens, 457–458
chemical control of mites, 453–454
cockroach allergens, 458–459
fungi, 455–457
humidity effects, 451–453
mite and dust control, 448–451
pollen, 459–460
quantitation of mite allergens, 454–455
sensitivity to, environmental control, 447–462
skin tests for, 209–210
Humidity, and mite growth, 451–453
Hydrocortisone, 82
Hypereosinophilic syndrome, 368
Hypersensitivity reactions, in atopic persons, 441–443
in cystic fibrosis, 393–406
allergic bronchopulmonary aspergillosis, 396–399
atopy, 393–396
drug reactions, 401–403
nasal polyposis, 399–401
food allergies, 300–301
in children, 345–346
immediate, eosinophil modulation of, 361
in urticaria and angioedema, 266
See also *Pneumonitis, hypersensitivity.*
Hypotension, 495
Hypothyroidism, nasal manifestations of, 164–165

IgE, antibody, in food allergies, 305–307
in vitro measurement of, 212–213
and atopy, genetics of, 237–239
in vitro tests, in occupational asthma, 321–322
Immune response, and allergenicity, 192
Immunization, active, principles of, 425–428
active versus passive, 425
administration routes, 427
antigen status, 426–427
immunologic status of host, 427–428
natural history of disease, 425–426
schedules and vaccine preparations, 428
adverse effects, 428–443
bacterial viruses, 434–436
hypersensitivity reactions in atopic persons, 441–443
in immunological compromised hosts, 438
passive immunization, 429–433
pathogenesis with immunologic basis, 440–441
toxoid reactions, 433–434
and viral antigen or route of administration, 439–440
viral vaccines, 436–438
Immunogenicity, and nature of allergens, 191
Immunologic disorders, allergy and otitis media, 374–375
and eosinophils, 367
nasal manifestations of, 165–171
Immunotherapy, 471–483
adverse reactions, 476–477
and allergic asthma, 249–250
for asthma in children, 342
controlled studies, 475–476
historical data, 472–473
immunologic changes, 479–480
modified forms of, 477–478
specific techniques, 473–475
Infections, and asthma, 245
in children, 336
and eosinophils, 362–364
and urticaria and angioedema, 269
Inflammation, and eosinophils, 361
Inflammatory mediators in allergic rhinitis, 37–55
and cold dry air challenge, 50–51
histamine, 45–46
kinins, kallikreins, and TAME esterases, 46–48
leukotrienes, 48–49
prostaglandins, 49–50
release mechanisms, 44–45
Inhalant allergies, in atopic dermatitis, 259–262
Inhalation food challenge, 309
Insect stings, allergy to, 277–283
acute management, 279
case reports, 278
clinical manifestation, 278–279
diagnosis, 279–281
pathogenesis, 278
prevention, 281–282
Ipratropium, 78

Kallikreins, 46–48
Ketotifen, 66, 465
Kinins, in allergic rhinitis, 46–48

Late respiratory systemic syndrome, 316
Leukocytotoxicity test, 9–10
Leukotrienes, 48–49
Life cycle, of eosinophils, 359
Light, and urticaria and angioedema, 268–269
Loeffler's syndrome, 364–365
Lower airway obstruction, 495
Lupus erythematosus, systemic, 170
Lymphoreticular diseases, and eosinophils, 367–368
Lysophospholipase, 357

Malignancies, and urticaria and angioedema, 270
Mast cells, mediator release from, **179–189**
  histamine release, 184–187
    enhancement of, 185–186
    extrinsic modulation of, 184
    inhibition of, 186–187
  intrinsic releasability, 183–184
  mucosal cytology, 17–18
  stimulus-response in, 180–182
Mastocytosis, systemic, 269
Mediators, of allergic rhinitis, 44–50
  after cold dry air challenge, 50–51
  histamine, 45–46
  kinins, kallikreins, and TAME esterases, 46–48
  leukotrienes, 48–49
  prostaglandins, 49–50
  release mechanisms, 44–45
  release from mast cells and basophils, **179–189**
  histamine release, 184–187
    enhancement of, 185–186
    extrinsic modulation of, 184
    inhibition of, 186–187
  intrinsic releasability, 183–184
  stimulus-response in, 180–182
Membrane of eosinophils, proteins associated with, 357–358
Menthol, in rhinitis pharmacotherapy, 61–63
Mercury, and allergic contact dermatitis, 416
Migraine, 149–156
  asthma as model for, 154
  common, 149
  definition of, 149
  diagnosis and management of, 154–156
    diet trial, 155–156
    history taking, 154
    laboratory tests, 155
    physical examination, 155
  epidemiology of, 149–150
    food allergy, 150
    immune abnormalities, 150
    seasonal attacks, 150
    weather effects, 150
  historical review, 150–153
Mites, allergen quantitation, 454–455
  chemical control, 453–454
  house dust control, 448–451
  humidity effects, 451–454
  skin tests for allergy, 209–210
Molds, allergens of, 197–199
  and asthma, 242
  skin tests for allergy, 210–212

NARES syndrome, 94–95
Nasal polyposis, in cystic fibrosis, 399–401
Nedocromil sodium, 65–66, 465–466
Neomycin, 416
Neoplasia, and eosinophil function, 367–368
Nerve supply, of nose, 41–42
Nickel, and allergic contact dermatitis, 413
Nonsteroidal anti-inflammatory agents, 68–69
Nose, allergen challenge, 28–31
  blood flow, 25–26
  histology of, 39–42
    blood supply, 41
    cells, 39–41
    innervation, 41–42
  mediator and irritant activity, 27–28
  mucociliary function and mucus hypersecretion, 26–27
  peak flow meters, 18–20
  physiology of, 38–39
  symptoms of systemic conditions, **159–174**
    hypothyroidism, 164–165
    immunologic disorders, 165–171
      Churg-Strauss syndrome, 166–168
      midline granuloma, 170
      polyarteritis nodosa, 166–168
      relapsing polychondritis, 169–170
      sarcoidosis, 168–169
      Sjögren's syndrome, 168
      systemic lupus erythematosus, 170
      therapy of, 170–171
      Wegener's granulomatosis, 166
    pregnancy, 160–163
    systemic medications, 163–164
  See also *Polyps, nasal.*
Nuclear magnetic resonance imaging, in sinusitis, 123–124

Otitis media with effusion, **133–145**
  epidemiology and natural history, 133–134
  etiology, 137–144
    immunologic and allergic aspects, 140–144
    infectious aspects, 137–139
  pathophysiology, 134–137

role of allergy, **371–381**
cause-effect perspective, 380
epidemiology, 374
eustachian tubes, 372–373
provocation studies, 375
immunologic mechanisms, 374–375
methodologic limitations of studies, 373–374
natural history, 371–372

Papular urticaria, 269
Paraphenylenediamine, 413–414
Parasitic infections, and eosinophils, 362–364
Passive immunization. See *Immunization.*
Patch testing, 417–419
Pathogenesis, of allergic contact dermatitis, 411–412
of allergic rhinitis, 44–51
of nasal polyps, 110
of otitis media with effusion, **133–145**
Pathogens, in sinus disease, 386
Pathophysiology, of allergy emergencies, 486–489
of migraine, 153–154
of otitis media with effusion, 134–137
of sinusitis, 119–121, 384–386
Peak flow meters, 18–20
Perfumes, 416
Phagocytosis, by eosinophils, 360
Pharmacotherapy of rhinitis, **57–91**
current and investigational, 61–85
anticholinergic agents, 78–79
antihistamine effects, 71–75
corticosteroids, 79–85
mediator release inhibitors, 63–71
azatadine, 70
azelastine, 70–71
calcium channel blockers, 66–68
cAMP increasers, 69–70
cromolyn sodium, 63–65
ketotifen, 66
nedocromil sodium, 65–66
nonsteroidal anti-inflammatory agents, 68–69
physiologic solution, 61–63
vasoconstrictors, 75–78
individualization of, 57–61
Physiologic solutions, in rhinitis pharmacotherapy, 61–63
Physiology, of nasal polyps, 109–110
of nose, 39–39
Plant dermatitis, 412
Pneumonitis, hypersensitivity, **313–330**
acute, 326–327
chronic, 327
diagnosis, 327
etiologic agents, 324
management, 327–328
pathogenesis and immunologic features, 325–326
Pollens, allergens of, 194–195
and asthma, 241–242
control of, 459–460
Polyarteritis nodosa, 166–168
Polychondritis, relapsing, 169–170
Polyps, nasal, **105–116**
anatomy, 106–108
and aspirin intolerance, 112–113
and atopy, 110–111
chronic nonallergic rhinitis, 96–98
differential diagnosis, 109
epidemiology, 106
histopathology, 108–109
history, 105
pathogenesis, 110
physiology, 109–110
treatment, 113–115
Pregnancy, nasal manifestations of, 160–163
rhinitis during, 100
Prostaglandins, in allergic rhinitis, 49–50
Proteins, eosinophil membrane-associated, 357–358
cell surface receptors, 357–358
eicosinoids, 358
enzymes, 358
lysophospholipase, 357
granule-associated, in eosinophils, 355–357
Provocation tests, for allergies, 213–214
subcutaneous-intracutaneous, 8–9
sublingual, 9
Psychological factors, and asthma in children, 336–337
and urticaria and angioedema, 270
Pulmonary anemia disease syndrome, 316
Pulmonary eosinophilia, 365–366
Pulmonary function tests, in occupational asthma, 322

Radiography, in chronic sinusitis, 121–122
Rantidine, 75
RAST testing, in upper respiratory tract allergy, 4–5
Receptors, eosinophil cell surface, 357–358
Respiratory tract disorders, and eosinophils, 364–366
Rhinitis, allergic and non-allergic, **221–234**
in children, 347–348
classification, 221–225
evaluation, 227–229
inflammatory mediators, **37–55**
immediate and late phase reactions, 43–44
pathogenesis of, 44–51, 225–226
cold dry air challenge, 50–51

Rhinitis *(Continued)*
allergic and non-allergic, pathogenesis of, histamine, 45–46
kinins, kallikreins, and TAME esterases, 46–48
leukotrienes, 48–49
mediator release mechanisms, 44–45
prostaglandins, 49–50
physiology and histology of nose, 38–42
prevalence of, 221
therapy, principles of, 229–232
evaluation tests, **15–35**
airflow obstruction tests, 18–25
fiberoptic rhinoscopy, 15–16
future prospects, 31–32
mediator and irritant effects, 27–28
mucociliary function and mucus hypersecretion, 26–27
mucosal cytology, 16–18
nasal blood flow, 25–26
nasal challenge with allergens, 28–31
nonallergic chronic syndromes, **93–103**
with eosinophilia (NARES) syndrome, 94–95
eosinophilic, 93–94
intermittent obstructive, of nonallergic asthma, 95–96
management of, 100–101
miscellaneous, 100
nasal polyposis, 96–98
noneosinophilic, 98–100
during pregnancy, 100
rhinitis medicamentosa, 98–99
vasomotor rhinitis, 98
and occupational asthma, 316
pharmacotherapy of, **57–91**
current and investigational, 61–85
individualization of, 57–61
See also *Upper respiratory tract allergy.*
Rhinitis medicamentosa, 98–99
Rhinomanometry, 21–25
Rubber, and allergic contact dermatitis, 414

Saline, in rhinitis pharmacotherapy, 61
Sarcoidosis, 168–169
Sinusitis, **383–391**
anatomy and function, 383–384
chronic, **117–132**
and asthma, 128–129
in children, 127–128, 337
complications of, 128
diagnosis of, 118
imaging techniques, 121–124
antral puncture, 124
computed tomography, 123
fiberoptic rhinoscopy, 124
nuclear magnetic resonance imaging, 123–124
other modalities, 124
plain radiography, 121–122
plain tomography, 122–123
transillumination, 121
ultrasound, 123
medical management, 124–126
pathophysiology of, 119–121
surgical management, 126–127
clinical presentation, 386–387
complications of, 390
diagnostic methods, 387–388
management of, 388–390
pathogens, 386
pathophysiology and predisposing factors, 384–386
Sjögren's syndrome, 168
Skin disorders, and eosinophils, 366–367
Skin tests, 207–212
for food allergies, 304–305
for house dust and mite allergy, 209–210
for mold allergy, 210–212
for occupational asthma, 321–322
for upper respiratory tract allergy, 2–5
intracutaneous testing, 3
multiple puncture technique, 3
positive and negative controls, 4
prick testing, 3
scoring system, 4
Smoking, and asthma, 247–248
Staphylococcal antigens, 260
Surgery, for sinusitis, 126–127

TAME esterases, 46–48
Temperature, and cold urticaria, 268, 273–274
Terfenadine, 74, 463–464
Titration, intracutaneous, 6–8
Tomography, computed, of airflow obstruction, 18
in chronic sinusitis, 123
plain, in chronic sinusitis, 122–123
Toxoids, adverse reactions, 433–434
Transient pulmonary eosinophilia, 364–365
Transillumination, in chronic sinusitis, 121
Tree allergens, 197
Trimetallic anhydride allergic asthma, 316
Trimethoprim-sulfamethoxazole reactions in AIDS, 294–295

Ultrasound, in chronic sinusitis, 123
Upper airway obstruction, 493–495
Upper respiratory disorders, allergic headaches, **147–157**
allergy, diagnosis of, **1–13**
classical evaluation, 1–5
diagnosis, 5

history, 1–2
laboratory workup, 2–5
physical examination, 2
controversial diagnostic approaches, 6–11
candidiases hypersensitivity syndrome, 10
clinical ecology, 10–11
intracutaneous titration, 6–8
leukocytotoxicity test, 9–10
subcutaneous-intracutaneous provocative testing and neutralization, 8–9
sublingual provocative testing and desensitization, 9
otitis media with effusion, **133–145**
rhinitis, allergic, **37–55**
evaluation tests, **15–35**
nonallergic chronic syndromes, **93–103**
pharmacotherapy of, **57–91**
sinusitis, **117–132**
and systemic conditions, **159–174**
Urticaria and angioedema, **265–276**, 495–496
classification and etiology of, 265–270
anaphylactoid, 266–267
aspirin and other agents, 267
hereditary angioedema, 266–267
histamine releasing agents, 267
collagen vascular disease, 270
endocrine factors, 270
episodic, with eosinophilia, 270
immunologic, 265–266
infections, 269
malignancies, 270
papular urticaria, 269
physical, 267–269
mechanical, 267–268
temperature, 268
psychogenic factors, 270
systemic mastocytosis, 269
urticaria pigmentosa, 269
urticaria vasculitis, 269–270
diagnosis, 270–271
management, 271–274

Vaccines, adverse reactions to, **423–445**
active immunization principles, 425–428
active versus passive immunization, 425
administration routes, 427
antigen status, 426–427
immunologic status of host, 427–428
natural history of disease, 425–426
schedules and preparations, 428
adverse effects, 428–443
with bacterial vaccines, 434–436
hypersensitivity reactions in atopic persons, 441–443
in immunologically compromised hosts, 438
in passive immunization, 429–433
pathogenesis with immunologic basis, 440–441
toxoid reactions, 433–434
viral antigen or route of administration, 439–440
and viral vaccines, 436–438
Vasoconstrictors, in rhinitis pharmacotherapy, 75–78
oral, 75–76
topical, 76–78
Vasomotor rhinitis, 98
Viral vaccines, 436–438
immunologic complications, 438
nonimmunologic complications, 436–438

Weather and seasonal effects on migraine, 150
Weed allergens, 196–197
Wegener's granulomatosis, 166
Workplace challenges, 322

X-rays, sinus, in upper respiratory tract allergy, 2
Xanthine drugs, 466–467